Australia, Oct. 15 -- Iambic Therapeutics Inc., owns the trademark (2516238) for 'ENCHANT' till Jan. 23, 2035.

Status: registered: Registered/protected

Class: 42 [Technical scientific consultation and product development for others in the fields of science, (excluding software and computer sciences), chemistry, physics, biology, physical chemistry, chemical physics, molecular engineering, materials science, catalysis, biochemistry, computational chemistry (excluding software and computer sciences), chemical engineering, medicine, and healthcare; development of materials, chemicals, and pharmaceuticals; research and development of pharmaceutical preparations and substances for use in clinical trials; research and development of treatment protocols for use in clinical trials; scientific and technological services, namely, research and design in the field of computational chemistry (excluding software and computer sciences), chemistry, biology, physics, physical chemistry, chemical physics, molecular engineering, materials science, catalysis, biochemistry, technology, chemical engineering, medicine and healthcare, and design and optimization of molecules, materials, catalysts, chemicals, and drugs; chemistry services in the nature of drug, materials, chemicals, and molecular discovery services, and product development services; chemical research and chemistry consultation in the field of drug, materials, chemicals, and molecular development; providing online non-downloadable software for simulations for drug, materials, chemicals, and molecular discovery; software as a service (SAAS) services featuring computer software platforms for use in optimizing drug, materials, chemicals, and molecular discovery; platform as a service (PAAS) featuring computer software platforms for use in optimizing drug, materials, chemicals, and molecular discovery; software as a services (SAAS) services in the nature of hosting cloud-based computing featuring software for the development of new molecules and designing and discovering molecules, drugs, and other molecular products; research and development of pharmaceutical drugs to treat diseases utilizing a proprietary drug discovery platform; drug discovery services; providing online non-downloadable computer software using artificial intelligence and machine learning for predicting properties of molecules and discovering molecules in the fields of science (excluding software and computer sciences), chemistry, physics, biology, physical chemistry, chemical physics, molecular engineering, materials science, catalysis, biochemistry, computational chemistry (excluding software and computer sciences), artificial intelligence, technology, computer science, chemical engineering, medicine, and healthcare; providing online non-downloadable computer software for use in the research and development of materials, chemicals, catalysts, and pharmaceutical products including pharmaceutical preparations and medicines; platform as a service (PAAS), namely, providing software platforms using artificial intelligence and machine learning for predicting properties of molecules and discovering molecules in the fields of science, chemistry, physics, biology, physical chemistry, chemical physics, molecular engineering, materials science, catalysis, biochemistry, computational chemistry (excluding software and computer sciences), chemical engineering, medicine, and healthcare; platform as a service (PAAS), namely, providing artificial intelligence software platforms for use in the research and development of materials, chemicals, catalysts, and pharmaceutical products including pharmaceutical preparations and medicines; software as a service (SAAS), namely, providing software using artificial intelligence and machine learning for predicting properties of molecules and discovering molecules in the fields of science, chemistry, physics, biology, physical chemistry, chemical physics, molecular engineering, materials science, catalysis, biochemistry, computational chemistry (excluding software and computer sciences), chemical engineering, medicine, and healthcare; software as a service (SAAS), namely, providing artificial intelligence software for use in the research and development of materials, chemicals, catalysts, and pharmaceutical products including pharmaceutical preparations and medicines; providing online non-downloadable software, namely, software for use in designing and developing, deep learning, reinforcement learning, building neural networks, tree search, high performance computing, distributed computing, cloud computing, analytics and data mining, virtual reality, augmented reality in the fields of science, chemistry, physics, biology, physical chemistry, chemical physics, molecular engineering, materials science, catalysis, computational chemistry, technology, computer science, chemical engineering, medicine, and healthcare; providing online non-downloadable computer software for use in determining properties or physical characteristics of organic compounds, inorganic compounds, organic materials, inorganic materials, and any mixtures thereof; scientific and technological services, namely, scientific and technical consulting, scientific research, development and design of computer software and technology in the fields of analytics and data mining, data analysis, data transformation, data visualization, statistical analysis, artificial intelligence, machine learning and virtual reality, science, chemistry, physics, biology and scientific research and new product design services provided in connection with the foregoing; industrial research services in the fields of artificial intelligence, machine learning, deep learning, reinforcement learning, building neural networks, tree search, distributed computing, cloud computing, analytics and data mining, virtual reality, chemistry, physics, and biology; industrial analysis in the fields of chemistry, physics, and biology; computer aided scientific analysis in the field of chemistry, physics, and biology; scientific research into organic compounds; scientific services for the analysis of organic compounds, inorganic compounds, organic materials, inorganic materials, and any mixtures thereof; crystallography services; medical and scientific research in the field of machine learning and models to evaluate drug compounds pharmacological properties; medical and scientific research services in the field of machine learning models to evaluate bioactivity and pharmacological properties of drug compounds; medical and scientific research services in the field of machine learning models to generate and evaluate drug compounds for specific pharmacological and bioactivity effects and results; medical and scientific research services in the field of machine learning models to evaluate drug compounds and their efficacy and side effects for purposes of clinical trials; medical and scientific research services in the field of machine learning models to generate and evaluate treatment protocols for purposes of clinical trials.]

Type of Mark: Word

Date of Acceptance: Aug. 7

Registration Advertised: Oct. 14

For further details contact Gilbert + Tobin Lawyers.

The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2516238.

Disclaimer: Curated by HT Syndication.